|Application ||IHC-P-Leica, WB, E|
|Other Accession||Q9Z2D6, P51608, Q95LG8|
|Other Names||Methyl-CpG-binding protein 2, MeCp-2 protein, MeCp2, MECP2|
|Target/Specificity||This MeCP2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 400-428 amino acids from human MeCP2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||MeCP2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Provided below are standard protocols that you may find useful for product applications.
DNA methylation is the major modification of eukaryotic genomes and plays an essential role in mammalian development. Human proteins MECP2, MBD1, MBD2, MBD3, and MBD4 comprise a family of nuclear proteins related by the presence in each of a methyl-CpG binding domain (MBD). Each of these proteins, with the exception of MBD3, is capable of binding specifically to methylated DNA. MECP2, MBD1 and MBD2 can also repress transcription from methylated gene promoters. In contrast to other MBD family members, MECP2 is X-linked and subject to X inactivation. MECP2 is dispensible in stem cells, but is essential for embryonic development. MECP2 gene mutations are the cause of some cases of Rett syndrome, a progressive neurologic developmental disorder and one of the most common causes of mental retardation in females.
dos Santos, J.M., et al., Neurosci. Lett. 379(1):13-16 (2005).
Ylisaukko-Oja, T., et al., Am J Med Genet A 132(2):121-124 (2005).
Schanen, C., et al., Am J Med Genet A 126(2):129-140 (2004).
Shibayama, A., et al., Am. J. Med. Genet. B Neuropsychiatr. Genet. 128(1):50-53 (2004).
Fang, J.Y., et al., World J. Gastroenterol. 10(23):3394-3398 (2004).